Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer

Expert Opinion on Investigational Drugs

Volumn 16, Issue 4, 2007, Pages 467-476

  Cabebe, Elwyn ^a   Fisher, George A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Drug development; Oral therapy; Pancreatic cancer; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PKI 116; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIANGIOGENIC ACTIVITY; ASTHENIA; ATAXIA; BLISTER; BLOOD TOXICITY; BRAIN HEMORRHAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FATIGUE; FOOT DISEASE; GASTROINTESTINAL STROMAL TUMOR; HAND DISEASE; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; KIDNEY CANCER; LETHARGY; LIMB PAIN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELENA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PROGNOSIS; PROTEINURIA; PRURITUS; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TUMOR VASCULARIZATION; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 34147145539     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.4.467     Document Type: Review

References (75)

1. JEMAL A, SIEGAL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
2. CONLON KC, KLIMSTRA DS, BRENNAN MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg. (1996) 223:273-279.
3. HERTEL LW, BODER GB, KROIN JS et al.: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. (1990) 50:4417-4422.
4. GRUNEWALD R, ABBRUZZESE JL, TARASSOFF P, PLUNKETT W: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother. Pharmacol. (1991) 27:258-262.
5. ABBRUZZESE JL, GRUNEWALD R, WEEKS EA et al.: A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. (1991) 9:491-498.
6. BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
7. KINDLER HL, FRIBERG G, STADLER WM et al.: Bevacizumab (B) plus gemcitabine (G) in patient (patients) with advanced pancreatic cancer (PC): Updated results of a multi-center Phase II trial. Proc Am. Soc. Clin. Oncol. (2004):4008 (Abstract).
8. FOLKMAN J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. (1972) 175:409-416.
9. ELLIS LM, TAKAHASHI Y, LIU W et al.: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist (2000) 5:11-15.
10. FAN TP, JAGGAR R, BICKNELL R: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci. (1995) 16:57-66.
11. SEED M: Angiogenesis inhibition as a drug target for disease: an update. Expert Opin. Investig. Drugs (1996) 5:1617-1636.
12. AUGUSTIN H: Antiangiogenic tumour therapy: will it work? Trends Pharmacol. Sci. (1998) 19:216-222.
13. FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182.
14. BUCHLER P, REBER H, BUCHLER MW et al.: VEGF-RII influences the prognosis of pancreatic cancer. Ann. Surg. (2002) 236:738-749.
15. DVORAK H: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. (2002) 20(21):4368-4380.
16. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353.
17. HANAHAN D, CHRISTOFORI G, NAIK P, ARBEIT J: Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur. J. Cancer (1996) 32A:2386.
18. PUGH CW, RADCLIFFE PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. (2003) 9(6):677-684.
19. CHEN Y, SHI G, XIA W et al.: Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res. (2004) 64(20):7302-7210.
20. LIOTTA LA, STEEG PS, STETLER-STEVENSON WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 64:327-336.
21. SENGER RD, VAN DE WATER L, BROWN LF et al.: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metast. Rev. (1993) 12:303-324.
22. BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathol. (1995) 26:86-91.
23. CROSS MJ, DIXELIUS J, MATSUMOTO T, CLAESSON-WELSH L: VEGF-receptor signal transduction. Trends Biochem. Sci. (2003) 28(9):488-494.
24. FERRARA N, GERBER H, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669-676.
25. KOLCH W, MARTINY-BARON G, KIESER A et al.: Regulation of the expression of VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res. Treat. (1995) 36:139-155.
26. BREIER G, RISAU W: The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol. (1996) 6:454-456.
27. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57(20):4593-4599.
28. GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19(3):843-850.
29. BAKER CH, SOLORZANO CC, FIDLER IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. (2002) 62:1996-2003.
30. HURWITZ HI, FEHRENBACHER L, HAINSWORTH JD et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. (2005) 23(15):3502-3508.
31. GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol. (2005):2 (Abstract).
32. MILLER K: E2100: a Phase III trial of paclitaxel versus paclitaxel/ bevacizumab for metastatic breast cancer. Clin. Breast Cancer (2003) 3:421-422.
33. SANDLER A, GRAY R, BRAHMER JR et al.: Randomized Phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc. Am. Soc. Clin. Oncol. (2005):LBA4 (Abstract).
34. ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. (2005) 23:4510a
35. ABRAMS TJ, LEE LB, MURRAY LJ et al.: SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2(5):471-478.
36. MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24:16-24.
37. MAKI RG, FLETCHER JA, HEINRICH C et al.: Results from a continuation trial of SU11248 in patients (patients) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J. Clin. Oncol. (2005) 23(16S):818s (Abstract 9011).
38. DEMETRI GD, VAN OOSTEROM AT, BLACKSTEIN M et al.: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (patients) following failure of imatinib for metastatic GIST. Proc. Am. Soc. Clin. Oncol. (2005) 23:4000a.
39. KARAYIANNAKIS AJ, BOLANAKI H, SYRIGOS KN et al.: Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett. (2003) 194(1):119-124.
40. BOCKHORN M, TSUZUKI Y, XU L et al.: Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin. Cancer Res. (2003) 9:4221-4226.
41. KINDLER HL, FRIBERG G, STADLER WM et al.: Bevacizumab (B) plus gemcitabine (G) in patient (patients) with advanced pancreatic cancer (PC): updated results of a multi-center Phase II trial. Proc. Am. Soc. Clin. Oncol. (2004) 22(14S):4009.
42. BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15(6):2403-2413.
43. WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60:2178-2189.
44. DREVS J, HOFMANN I, HUGENSCHMIDT H et al.: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60:4819-4824.
45. SOLORZANO CC, BAKER CH, BRUNS CJ et al.: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. (2001) 15(5):359-370.
46. BAKER CH, SOLORZANO CC, FIDLER IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. (2002) 62(7):1996-2003.
47. THOMAS AL, MORGAN B, HORSFIELD MA et al.: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. (2005) 23(18):4162-4171.
48. HECHT JR, TRARBACH T, JAEGER E et al.: A randomized, double-blind, placebo-controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc. Am. Soc. Clin. Oncol. (2005) 23(16S Suppl. 1):3.
49. KUO T, FITZGERALD AM, KAISER H, SIKIC BI, FISHER GA: A Phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S Suppl. 1):4122.
50. CIARDIELLO F, CAPUTO R, DAMIANO V et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. (2003) 9(4):1546-1556.
51. XIONG HQ, ABBRUZZESE JL: Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. (2002) 29(5 Suppl 14):31-37.
52. RYAN AJ, WEDGE SR: ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer (2005) 1:S6-S13 (Supplement).
53. BRUNS CJ, KOHL G, GUBA M et al.: Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR (KDR)-TKI), in a model of ZD1839 (Iressa) resistance. Proc. Am. Soc. Clin. Oncol. (2003) 44:4880.
54. HURWITZ H, HOLDEN SN, ECKHARDT SG et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:325 (Abstract).
55. MINAMI H, EBI H, TAHARA M et al.: A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2003):776 (Abstract).
56. LEE D: Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin. Lung Cancer (2005) 7(2):89-91.
57. JOHNSON BE, MA P, WEST H et al.: Preliminary Phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):7102.
58. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Cin. Oncol. (2003) 21:2237-2246.
59. MILLER KD, TRIGO JM, WHEELER C et al.: A multicenter Phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. (2005) 11(9):3369-3376.
60. INAI T, MANCUSO M, HASHIZUME H et al.: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. (2004) 165(1):35-52.
61. RUGO HS, HERBST RS, LIU G et al.: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. (2005) 23(24):5474-5483.
62. RINI B, RIXE O, BUKOWSKI R et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):4509.
63. SPANO JP, MOORE M, KIM S et al.: A Phase I study of Axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(Suppl. 18S):13092.
64. WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64(19):7099-7109.
65. HEIM M, SCHARIFI M, ZISOWSKY J et al.: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs (2005) 16(2):129-136.
66. STRUMBERG D, RICHLY H, HILGER RA et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. (2005) 23(5):965-972.
67. RATAIN MJ, EISEN T, STADLER WM et al.: Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. (2005) 23(Suppl. 16S):4544.
68. ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. (2005) 23(Suppl. 16S):4510.
69. SIU LL, TAKIMOTO CH, AWADA A et al.: A Phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. Proc. Am. Soc. Cin. Oncol. (2004) 22(Suppl. 14S):3059.
70. TRAXLER P, ALLEGRINI PR, BRANDT R et al.: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. (2004) 64(14):4931-4941.
71. YOKOI K, THAKER PH, YAZICI S et al.: Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. (2005) 65(9):3716-3725.
72. BUCHDUNGER E, CIOFFI CL, LAW N et al.: Ab1 protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. (2000) 295(1):139-145.
73. BASELGA J, ROJO F, DUMEZ H et al.: Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen. Proc. Am. Soc. Clin. Oncol. (2005) 23(Suppl. 16S):3028.
74. WEDGE SR, KENDREW J, HENNEQUIN LF et al.: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. (2005) 65(10):4389-4400.
75. DREVS J, MEDINGER M, MROSS K et al.: Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. Proc. Am. Soc. Clin. Oncol. (2005) 23(Suppl. 16S):3002.